Latest updates on the COVID-19 outbreak
December 19, 2020
Dear valued customer,
PolyPeptide’s six sites are working round the clock to meet delivery timelines on several important projects while enabling social distancing. Teams all across our company are going above and beyond to meet our commitments to customers and save patient lives.
To keep employees safe and sites running as fully as possible, we will continue to:
- Stagger schedules to support social distancing.
- Offer work-from-home options.
- Offer non-overlapping team shifts where possible and extend hours of operation to support social distancing
- Provide masks and appropriate PPE.
- Rigorously clean work areas regularly.
As a Global Leader in Peptide Manufacturing and Development, the PolyPeptide Group has been actively engaged on projects with clients who are developing peptide-based therapies and vaccines to combat COVID-19. The Group has been active in supporting multiple COVID-19 projects, and partners with a variety of global pharmaceutical, biotech and research institutions to support their urgent research in the fight against disease and the serious symptoms caused by COVID-19. In addition to our involvement in the manufacture of the Matrix M adjuvant components for the Novavax COVID-19 vaccine currently in clinical trials, The PolyPeptide Group is working on several projects that can treat COVID-19 symptoms, especially Acute Respiratory Distress Syndrome (ARDS) a common effect of the virus.
Feel free to reach out to us for more information Contact us
Wishing you and your family good health.
Jane Salik, CEO